Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute

Launched by CHANG GUNG MEMORIAL HOSPITAL · Jan 12, 2016

Keywords

ClinConnect Summary

This clinical trial is studying the effects of different treatments for patients diagnosed with primary central nervous system lymphoma (PCNSL), a rare type of brain cancer. Researchers want to understand how these treatments, which include a combination of brain radiation and chemotherapy, affect patients' thinking, memory, and overall quality of life over time. The trial aims to gather information on about 25 newly diagnosed patients at a single cancer center, using various tests to assess cognitive function and brain health.

To be eligible for this study, patients must have a confirmed diagnosis of non-Hodgkin's lymphoma through a brain biopsy and undergo specific imaging tests that show signs of the disease. Participants should also have a normal health evaluation and be HIV-negative. Throughout the trial, participants can expect to undergo a series of standardized tests that assess their cognitive abilities and complete quality of life questionnaires. This research is important because it seeks to identify any lasting effects of treatment on brain function, helping to improve care for future patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients must have a histopathologic diagnosis of non-Hodgkin's lymphoma (NHL) by brain biopsy
• • A typical MRI/CT scan for primary CNS lymphoma is defined as the presence of hypo, iso, or hyperintense parenchymal contrast-enhancing (usually homogeneously) mass lesion(s)
• • Patients must have a normal or negative pre-treatment systemic evaluation including: i. A bone marrow aspirate and biopsy ii. CT scans of the chest, abdomen and pelvis iii. Patients must have adequate bone marrow reserve
• • Patients must be HIV-1 negative
• • Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment
• Exclusion Criteria:
• • A past history of major psychiatric disease
• • Prior cranial irradiation for any reasons
• • Other active primary cancer with the exception of basal cell carcinoma of skin and cervical carcinoma in situ
• • Pre-existing immunodeficiency such as renal transplant recipient